[1] Sung H,Ferlay J,Siegel RL,et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin,2021,71(3):209-249.
[2] 陈敏山. 中国肿瘤整合诊治指南-肝癌(2022精简版). 中国肿瘤临床,2022,49(17):865-873.
[3] Farinati F,Marino D,De Giorgio M,et al. Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma:both or neither? Am J Gastroenterol,2006,101(3):524-532.
[4] Han LL, Lv Y,Guo H,et al. Implications of biomarkers in human hepatocellular carcinoma pathogenesis and therapy. World J Gastroenterol,2014,20(30):10249-10261.
[5] Chen S,Chen H,Gao S,et al. Differential expression of plasma microRNA-125b in hepatitis B virus-related liver diseases and diagnostic potential for hepatitis B virus-induced hepatocellular carcinoma. Hepatol Res,2017,47(4):312-320.
[6] Feng H,Li B,Li Z,et al. PIVKA-ⅡII serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma. BMC Cancer,2021,21(1):401.
[7] Sterling RK,Jeffers L,Gordon F,et al. Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination,as biomarkers for hepatocellular carcinoma. Clin Gastroenterol Hepatol,2009,7(1):104-113.
[8] Ji J,Wang H,Li Y,et al. Diagnostic evaluation of des-gamma-carboxy prothrombin versus α-fetoprotein for hepatitis b virus-related hepatocellular carcinoma in china:a large-scale, multicentre study. PLoS One,2016,11(4):e0153227.
[9] Song P, Gao J,Inagaki Y,et al. Biomarkers:evaluation of screening for and early diagnosis of hepatocellular carcinoma in Japan and Cchina. Liver Cancer,2013,2(1):31-39.
[10] Izumi N. Diagnostic and treatment algorithm of the Japanese society of hepatology:a consensus-based practice guideline.Oncology,2010,78(Suppl1):78-86.
[11] Liu Z,Wu M,Lin D,et al. Des-gamma-carboxyprothrombin is a favorable biomarker for the early diagnosis of alfa-fetoprotein-negative hepatitis B virus-related hepatocellular carcinoma. J Int Med Res,2020,48(2):300060520902575.
[12] Taketa K,Endo Y,Sekiya C,et al. A collaborative study for the evaluation of lectin-reactive alpha-fetoproteins in early detection of hepatocellular carcinoma. Cancer Res,1993,53(22):5419-5423.
[13] Park SJ,Jang JY,Jeong SW,et al. Usefulness of AFP,AFP-L3,and PIVKA-Ⅱ,and their combinations in diagnosing hepatocellular carcinoma. Medicine (Baltimore),2017,96(11):e5811.
[14] Shiraki K,Takase K,Tameda Y,et al. A clinical study of lectin-reactive alpha-fetoprotein as an early indicator of hepatocellular carcinoma in the follow-up of cirrhotic patients. Hepatology,1995,22(3):802-807.
[15] Zhang Z,Zhang Y,Wang Y,et al. Alpha-fetoprotein-L3 and Golgi protein73 may serve as candidate biomarkers for diagnosing alpha-fetoprotein-negative hepatocellular carcinoma. Onco Targets Ther,2015,9:123-129.
[16] Kladney RD,Bulla GA,Guo L,et al. GP73,a novel Golgi-localized protein upregulated by viral infection. Gene,2000,249(1-2):53-65.
[17] Kladney RD,Cui X,Bulla GA,et al. Expression of GP73,a resident Golgi membrane protein, in viral and nonviral liver disease. Hepatology,2002,35(6):1431-1440.
[18] Jing JS,Ye W,Jiang YK,et al. The value of GPC3 and GP73 in clinical diagnosis of hepatocellular carcinoma. Clin Lab,2017,63(11):1903-1909.
[19] Marrero JA,Romano PR,Nikolaeva O,et al. GP73,a resident Golgi glycoprotein,is a novel serum marker for hepatocellular carcinoma. J Hepatol,2005,43(6):1007-1012.
[20] Liu Y,Wang J,Yang R,et al. GP73-mediated secretion of AFP and GP73 promotes proliferation and metastasis of hepatocellular carcinoma cells. Oncogenesis,2021,10(10):69.
[21] Yuan JJ,Xu YD,Li H,et al. Magnetic resonance imaging and serum AFP-L3 and GP-73 in the diagnosis of primary liver cancer. J Oncol,2022,2022:1192368.
[22] Zhou F,Shang W,Yu X,et al. Glypican-3: Aa promising biomarker for hepatocellular carcinoma diagnosis and treatment. Med Res Rev,2018,38(2):741-767.
[23] Jiang D,Zhang Y,Wang Y,et al. Diagnostic accuracy and prognostic significance of Gglypican-3 in hepatocellular carcinoma:Aa systematic review and meta-analysis. Front Oncol,2022,12:1012418.
[24] Tahon AM,El-Ghanam MZ,Zaky S,et al. Significance of Gglypican-3 in early detection of hepatocellular carcinoma in cirrhotic patients. J Gastrointest Cancer,2019,50(3):434-441.
[25] Nakatsura T,Yoshitake Y,Senju S,et al. Glypican-3,overexpressed specifically in human hepatocellular carcinoma,is a novel tumor marker. Biochem Biophys Res Commun,2003,306(1):16-25.
[26] Zhang J,Zhang M,Ma H,et al. Overexpression of glypican-3 is a predictor of poor prognosis in hepatocellular carcinoma:Aan updated meta-analysis. Medicine (Baltimore),2018,97(24):e11130.
[27] Wang X,Song X,Zhuo W,et al. The regulatory mechanism of Hsp90alpha secretion and its function in tumor malignancy. Proc Natl Acad Sci USA,2009,106(50):21288-21293.
[28] Fu Y,Xu X,Huang D,et al. Plasma heat shock protein 90alpha as a biomarker for the diagnosis of liver cancer:an official,large-scale,and multicenter clinical trial. E Bio Medicine,2017,24:56-63.
[29] Su K,Liu Y,Wang P,et al. Heat-shock protein 90α is a potential prognostic and predictive biomarker in hepatocellular carcinoma:a large-scale and multicenter study. Hepatol Int,2022,16(5):1208-1219.
[30] Shen Q,Fan J,Yang XR,et al. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma:a large-scale,multicentre study. Lancet Oncol,2012,13(8):817-826.
[31] Zhu WL,Fan BL,Liu DL,et al. Abnormal expression of fibrinogen gamma (FGG) and plasma level of fibrinogen in patients with hepatocellular carcinoma. Anticancer Res,2009,29(7):2531-2534.
[32] Qiao W,Leng F,Liu T,et al. Prognostic value of prealbumin in liver cancer:a systematic review and meta-analysis. Nutr Cancer,2020,72(6):909-916.
[33] Moreira AJ,Rodrigues GR,Bona S,et al. Ductular reaction,cytokeratin 7 positivity,and gamma-glutamyl transferase in multistage hepatocarcinogenesis in rats. Protoplasma,2017,254(2):911-920.
[34] Huang L,Mo Z,Hu Z,et al. Diagnostic value of fibrinogen to prealbumin ratio and gamma-glutamyl transpeptidase to platelet ratio in the progression of AFP-negative hepatocellular carcinoma. Cancer Cell Int,2020,20:77. |
